Zarontin Solution
NDC Package 0071-2418-19

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Zarontin (ethosuximide) solution is a medication used alone or with other medications to prevent and control a certain type of seizure (absence or petit mal seizure). This formulation utilizes a solution delivery system. Marketed by Parke-davis Div Of Pfizer Inc, this product is identified by NDC 0071-2418 and is authorized under FDA application ANDA080258.

Identification & Billing

NDC Package Code
0071-2418-19
Package Description
1 BOTTLE, PLASTIC in 1 CARTON / 474 mL in 1 BOTTLE, PLASTIC
Product Code
0071-2418
11-Digit Billing Format
00071241819
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Zarontin
Non-Proprietary Name
Ethosuximide
Substance Name
Ethosuximide
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
ETHOSUXIMIDE 250 mg/5mL
Pharmacologic Class
Usage Information
This medication is used alone or with other medications to prevent and control a certain type of seizure (absence or petit mal seizure). It works by controlling the abnormal electrical activity in the brain that occurs during a seizure.

Regulatory & Marketing

Labeler Name
Parke-davis Div Of Pfizer Inc
Product Type
Human Prescription Drug
FDA Application #
ANDA080258
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-10-2020
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0071-2418-19 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 474 ml in 1 bottle, plastic of Zarontin, a human prescription drug labeled by Parke-davis Div Of Pfizer Inc. This solution is formulated for oral use and contains ethosuximide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Parke-davis Div Of Pfizer Inc on March 10, 2020. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used alone or with other medications to prevent and control a certain type of seizure (absence or petit mal seizure). It works by controlling the abnormal electrical activity in the brain that occurs during a seizure.

How is this Parke-davis Div Of Pfizer Inc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00071241819. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0071-2418-19
11-Digit CMS (5-4-2)
00071-2418-19

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.